Catalyst Pharmaceuticals Inc (CPRX)
Working capital turnover
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 491,734 | 460,482 | 434,475 | 411,347 | 398,204 | 348,393 | 302,949 | 256,480 | 214,203 | 191,755 | 170,465 | 153,717 | 140,833 | 133,539 | 126,902 | 120,142 | 119,073 | 118,181 | 119,761 | 118,994 |
Total current assets | US$ in thousands | 623,609 | 538,998 | 474,429 | 404,602 | 219,329 | 192,017 | 240,968 | 198,911 | 320,797 | 276,310 | 242,558 | 221,191 | 210,106 | 192,795 | 176,305 | 161,533 | 159,244 | 143,342 | 131,164 | 116,944 |
Total current liabilities | US$ in thousands | 120,678 | 105,395 | 92,318 | 79,566 | 76,063 | 57,806 | 52,503 | 56,709 | 57,588 | 44,681 | 22,488 | 22,938 | 27,063 | 20,614 | 16,135 | 14,436 | 22,756 | 18,232 | 20,210 | 17,636 |
Working capital turnover | 0.98 | 1.06 | 1.14 | 1.27 | 2.78 | 2.60 | 1.61 | 1.80 | 0.81 | 0.83 | 0.77 | 0.78 | 0.77 | 0.78 | 0.79 | 0.82 | 0.87 | 0.94 | 1.08 | 1.20 |
December 31, 2024 calculation
Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $491,734K ÷ ($623,609K – $120,678K)
= 0.98
The working capital turnover ratio of Catalyst Pharmaceuticals Inc has fluctuated over the analyzed period. The ratio indicates how effectively the company is using its working capital to generate revenue. A higher ratio suggests efficient utilization of working capital, while a lower ratio may indicate inefficiency or excess working capital.
The working capital turnover ratio declined from 1.20 on March 31, 2020, to 0.78 on December 31, 2021. This decrease could suggest a decrease in sales relative to the working capital employed during this period. However, it is worth noting that there was a significant improvement in the ratio during the first quarter of 2023, jumping to 1.80, before gradually declining again.
Overall, the trend in the working capital turnover ratio of Catalyst Pharmaceuticals Inc indicates some fluctuations, with periods of both efficiency and inefficiency in utilizing working capital to generate revenue. Further analysis of the company's financial performance and operational efficiency would be needed to better understand the underlying factors driving these fluctuations.
Peer comparison
Dec 31, 2024